Serum erythropoietin and its placental expression in preeclampsia-complicated pregnancy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To define the significance of serum erythropoietin and its placental expression in the pathogenesis of preeclampsia. Subjects and methods. The case-control study enrolled 11 women without preeclampsia, 14 with moderate preeclampsia, and 14 with severe preeclampsia. The specific features of pregnancy and delivery were analyzed and production adequacy of erythropoietin and its placental expression were determined. Results. Cases of inadequate erythropoietin production were registered in preeclampsia, more commonly in severe one. The adequacy of erythropoietin production was lower in severe preeclampsia. The inadequate production of erythropoietin correlates with its enhanced placental expression in the symplastotrophoblast, capillary endothelium, and villous stromal macrophages with its decreased expression in the red blood cells of villous capillaries. The correlations of the indicators of erythropoietin status in pregnant women with obstetric complications (preeclampsia, placental insufficiency) are suggestive of the similar mechanisms of their development. A scheme of the involvement of erythropoietin in the pathogenesis of preeclampsia is proposed. Conclusion. Erythropoietin takes part in the pathogenesis of a number of obstetric complications, including preeclampsia; however, the significance of erythropoietin in the development of this abnormality calls for further investigation. The authors declare no conflicts of interest.

Full Text

Restricted Access

About the authors

Boris Ivanovich Medvedev

South Ural State Medical University, Ministry of Health of Russia

doctor of medical sciences, professor, the chair of Obstetrics and Gynecology

Elena Gennadyevna Syundyukova

South Ural State Medical University, Ministry of Health of Russia

Email: seg269@mail.ru
candidate of medical sciences, associate professor, the chair of Obstetrics and Gynecology

Sergey Lvovich Sashenkov

South Ural State Medical University, Ministry of Health of Russia

Email: sashensl@yandex.ru
doctor of medical sciences, professor, the chair of Normal Physiology

References

  1. Захаров Ю.М. Цитопротективные функции эритропоэтина. Клиническая нефрология. 2009; 1: 16-21.
  2. Fairchild B.D., Conrad K.P. Expression of the erythropoietin receptor by trophoblast cells in the human placenta. Biol. Reprod. 1999; 60(4): 861-70.
  3. Teramo K.A., Widness J.A. Increased fetal plasma and amniotic fluid erythropoietin concentrations: markers of intrauterine hypoxia. Neonatology. 2009; 95(2): 105-16.
  4. Zamudio S., Wu Y., Ietta F., Rolfo A., Cross A., Wheeler T. et al. Human placental hypoxia-inducible factor-1alpha expression correlates with clinical outcomes in chronic hypoxia in vivo. Am. J. Pathol. 2007; 170(6): 2171-9.
  5. Серов В.Н., Сухих Г.Т., ред. Клинические рекомендации. Акушерство и гинекология. 4-е изд. М.: ГЭОТАР-Медиа; 2014. 1024с.
  6. Ходжаева З.С., Акатьева А.С., Холин А.М., Сафонова А.Д., Вавина О.В., Муминова К.Т. Молекулярные детерминанты развития ранней и поздней преэклампсии. Акушерство и гинекология. 2014; 6: 14-9.
  7. Бурлев В.А. Неадекватная продукция эритропоэтина у беременных с гестозом и железодефицитной анемией. Voprosyi ginekologii, akusher-stva i perinatologii. 2007; 6(6): 16-20.
  8. Hershkovitz R., Ohel I., Sheizaf B., Nathan I., Erez O., Sheiner E. et al. Erythropoietin concentration among patients with and without preeclampsia. Arch. Gynecol. Obstet. 2005; 273(3): 140-3.
  9. Медведев Б.И., Сюндюкова Е.Г., Сашенков С.Л., Захаров Ю.М. Значение эритропоэтина в патогенезе развития преэклампсии. Вопросы гинекологии, акушерства и перинатологии. 2014; 13(4): 35-41.
  10. Yazihan N., Güler G., Kenar F., Salman B., Erkasap N., Uzuner K. Effect of erythropoietin on feto-placental development: the role of placental nitric oxide level in rat. New J. Med. 2007; 24: 213-6.
  11. Espada J., Brandan N.C., Dorado M. Molecular heterogeneity of human erythropoietin. Biochim. Biophys. Acta. 1974; 359(2): 369-78.
  12. Румянцев А.Г., Морщакова Е.Ф., Павлов А.Д. Эритропоэтин в диагностике, профилактике и лечении анемий. М.: Медицина; 2003. 448с.
  13. Криворучко А.Ю., Аксененко В.А., Квочко А.Н., Павлов Р.В. Продукция цитокинов культурой ворсин хориона больных поздним гестозом в условиях гипоксии. Журнал акушерства и женских болезней. 2000; 49(4): 82-5.
  14. Макарова Н.А., Захаров Ю.М. Влияние количественных соотношений эритропоэтина и опухольнекротизирующего фактора-А на структурно-функциональные свойства миокарда у больных с сердечной недостаточностью. Вестник Уральской медицинской академической науки. 2011; 1: 60-3.
  15. Toth B., Fischl A., Scholz C., Kunze S., Friese K., Jeschke U. Erythropoietin and erythropoietin receptor expression in normal and disturbed pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008; 140(2): 192-200.
  16. Jain V., Lim M., Longo M., Fisk N.M. Inhibitory effect of erythropoietin on contractility of human chorionic plate vessels. Am. J. Obstet. Gynecol. 2006; 194(1): 246.
  17. Глушков В.С., Сторожок С.А. Запрограммированная гибель эритроцитов (эриптоз). Вестник Уральской академической науки. 2009; 2(25): 99.
  18. Lang F., Lang E., Föller M. Physiology and pathophysiology of eryptosis. Transfus. Med. Hemother. 2012; 39(5): 308-14.
  19. Ray J., Jurisicova A., Caniggia I. IFPA Trophoblast Research Award Lecture: the dynamic role of Bcl-2 family members in trophoblast cell fate. Placenta. 2009; 30(Suppl. A.): 96-100.
  20. Staun-Ram E., Goldman S., Shalev E. Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion. Reprod. Biol. Endocrinol. 2009; 7: 135-8.
  21. Сюндюкова Е.Г., Медведев Б.И., Сашенков С.Л., Зайнетдинова Л.Ф., Канайкина А.Ю. Гистоморфологические особенности плаценты при преэклампсии. Медицинский вестник Башкортостана. 2014; 9(5): 104-7.
  22. Медвинский И.Д. Роль синдрома системной воспалительной реакции в патогенезе гестоза (прогноз развития, диагностика, выбор метода анестезиологической защиты): автореф. дисс.. д-ра мед. наук. Челябинск; 2004. 56c.
  23. Сельков С.А., Соколов Д.И. Иммунологические механизмы контроля развития плаценты. Журнал акушерства и женских болезней. 2010; 59(1): 6-10.
  24. Медведев Б.И., Сюндюкова Е.Г., Сашенков С.Л. Исходы беременности и родов у женщин с гестозом и анемией. Акушерство и гинекология. 2012; 2: 24-9.
  25. Hu R., Cheng Y., Jing H., Wu H. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. Shock. 2014; 42(4): 327-36.
  26. Santhanam A.V., d’Uscio L.V., Katusic Z.S. Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling. J. Neurochem. 2014; 131(4): 521-9.
  27. Li X.J., Zhang G.X., Sun N., Sun Y., Yang L.Z., Du Y.J. Protective effects of erythropoietin on endotoxin-related organ injury in rats. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013; 33(5): 680-6.
  28. Yang X.F., He Y., Li H.Y., Liu X., Chen H., Liu J.B. et al. Hepatoprotective effects of erythropoietin on D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice. Mol. Med. Rep. 2014; 10(1): 555-9.
  29. Liu P., Liu X., Liou A.K., Xing J., Jing Z., Ji X. et al. The neuroprotective mechanism of erythropoietin-TAT fusion protein against neurodegeneration from ischemic brain injury. CNS Neurol. Disord. Drug Targets. 2014; 13(8): 1465-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies